Two-year outcomes of denosumab treatment for osteoporosis comparing the effects of calcium and vitamin D supplementation Authors: Young-Ho Cho, Seong-Eun Byun, Hwan-Hee Lee Published: 2025 ABSTRACT AbstractCalcium and vitamin D supplementation is commonly recommended in conjunction with osteoporosis treatment. However, some patients are unable to tolerate or take these supplements due to various factors. This study aims to assess the impact of calcium and vitamin D supplementation on bone mineral density (BMD) changes over a two-year period in patients treated with denosumab, comparing those who received supplements with those who did not. This retrospective study included 344 patients who had received at least four doses of denosumab. Patients were divided into two groups: those who received calcium and vitamin D supplementation and those who did not. BMD was measured annually at the lumbar spine, total hip, and femoral neck, and denosumab efficacy was assessed by calculating the percentage change in BMD from baseline. We also evaluated BMD changes according to patients’ prior osteoporosis treatments and history of osteoporotic fractures. In addition, a subgroup analysis was conducted among treatment-naïve patients, comparing those who received denosumab alone with those who received denosumab combined with calcium and vitamin D supplementation. The study cohort consisted of 328 women, with a mean age of 70.50 ± 9.48 years. Statistically significant differences were found between the two groups regarding prior osteoporosis treatment (P = 0.004) and baseline lumbar spine BMD (P = 0.027). However, no significant differences were observed in BMD changes at the lumbar spine, total hip, or femoral neck after one and two years of denosumab treatment, regardless of calcium and vitamin D supplementation. The type of prior osteoporosis medication and the presence of low-energy fragility fractures did not significantly affect BMD changes at either time point. In treatment-naïve patients (n = 209), BMD gains did not differ significantly between those with and without supplementation. Notably, none of the patients reported experiencing adverse events such as injection site infections, myalgia, or symptomatic hypocalcemia. The two-year treatment with denosumab resulted in improvements in BMD that were independent of calcium and vitamin D supplementation. These findings suggest that denosumab may increase BMD regardless of supplementation, though further studies are warranted to confirm this relationship.Keywords: Denosumab, Calcium, Vitamin D, Supplements, Bone mineral densitySubject terms: Outcomes research, Drug therapy Introduction Receptor activator of nuclear factor-kappa B ligand (RANKL) is a protein expressed by osteoblasts that binds to the receptor activator of nuclear factor-kappa B (RANK), initiating the differentiation, activation, and survival of osteoclast1.The activation of the RANKL/RANK pathway is a central mechanism in osteoclast-mediated bone resorption, which plays a pivotal role in the pathogenesis of postmenopausal osteoporosis. Osteoprotegerin (OPG), an endogenous soluble decoy receptor, regulates the RANKL/RANK pathway by binding to RANKL and inhibiting its interaction with RANK, thus reducing bone resorption2,3. Denosumab is a fully human monoclonal antibody (IgG2) that binds to RANKL with high affinity and specificity, thereby blocking its interaction with RANK and mimicking inhibitory effects of OPG4. In previous clinical trials, denosumab treatment for 12 months increased BMD by approximately 3.0–6.7% at the lumbar spine and 1.9–3.6% at the total hip in postmenopausal women with osteoporosis5. All participants in this trial were prescribed daily oral supplements containing 1 g of elemental calcium and 400 IU of vitamin D. Similar results have been observed in other studies investigating osteoporosis medications, where nearly all patients were also given calcium and vitamin D supplementation6–10. However, it is noteworthy that several large randomized controlled trials have also achieved comparable improvements in BMD and fracture reduction without providing routine calcium supplementation, indicating that the efficacy of antiresorptive therapy may not be entirely dependent on additional calcium intake11–16. Certain patients, however, may be unable to tolerate such supplements due to conditions such as kidney stones, constipation, or gastrointestinal disorders. To the best of our knowledge, there are no studies that explore the effects of denosumab treatment in the absence of calcium and vitamin D supplementation. Therefore, in the current study, we aimed to investigate the changes in BMD between two groups of patients treated with denosumab for osteoporosis: those who received calcium and vitamin D supplementation versus those who did not, over a 2-year treatment period. Patients and methods This study was approved by the Institutional Review Board (IRB) of Daegu Fatima Hospital (IRB No. DFH 2024-11-002), and all methods were performed in accordance with relevant guidelines and regulations, including the Declaration of Helsinki. The requirement for informed consent was waived by the IRB due to the retrospective nature of the study. We evaluated men and women over 60 years of age with a BMD T-score of less than − 2.5 at the lumbar spine, total hip, or femoral neck who had been treated with denosumab for more than 2 years, starting in 2018. Electronic medical records of 1,383 patients who received denosumab during this period were reviewed. All patients received subcutaneous administration of 60 mg of denosumab every 6 months. We excluded patients who received fewer than four doses of denosumab, those who did not undergo regular BMD testing, patients who had BMD measurements at other institutions, those with secondary osteoporosis, dialysis-dependent patients, and patients for whom BMD measurements could not be performed in the same anatomical areas due to spine or hip surgery during follow-up. All patients were recommended to take more than 1,000 mg of calcium and 400 IU of vitamin D daily. However, some patients refused these supplements due to side effects such as kidney stones, constipation, and gastrointestinal discomfort. Patients were divided into two groups: one group received denosumab along with calcium and vitamin D supplements, while the other group did not receive any supplementation. Basic demographic data, including age, sex, and body mass index (BMI), were collected. To assess the effects of 2 years of denosumab therapy on BMD, dual-energy X-ray absorptiometry (DXA) was performed using a Hologic Discovery W scanner (Hologic, Marlborough, MA). The least significant change for this model was 0.022 g/cm2. BMD tests were conducted following the standardized methods recommended by the International Society for Clinical Densitometry17. The effectiveness of denosumab was evaluated by measuring the percent change from baseline in BMD of the lumbar spine, total hip, and femoral neck at both 12 and 24 months, depending on whether patients received calcium and vitamin D supplements. We also assessed changes in BMD based on patients’ history of prior osteoporosis treatment and the presence of osteoporotic fractures. Furthermore, a subgroup analysis was conducted including only treatment-naïve patients, who were divided into those receiving denosumab alone and those receiving denosumab in combination with calcium and vitamin D supplementation. Descriptive analysis summarized categorical variables by number and percentage. Continuous outcomes were summarized as mean ± standard deviation (SD). To assess differences in basic demographic data between the two groups, T-tests and Fisher’s exact tests were used. To determine the significance of BMD changes at the lumbar spine, total hip, and femoral neck between the two groups at 1 year and 2 years, one-way ANOVA was employed. A p-value of less than 0.05 was considered statistically significant. Data analysis was performed using SPSS version 21.0 (SPSS, Inc., Chicago, IL, USA). Results A total of 344 patients were included in the current study, consisting of 328 women, with a mean age of 70.50 ± 9.48 years. Other basic demographic data for all patients are presented in Table 1. Table 1Basic demographics of all subjects.VariableN = 344SexMale16(4.7)Female328(95.3)Age(years)70.50 ± 9.48 < 6591(26.5)65–74116(33.7) ≥ 75137(39.8)PrescriptionDmab* only92(26.7)Dmab + Ca†, Vit D252(73.3)Past osteoporosis treatmentNo209(60.8)Yes135(39.2)BP‡103(29.9)SERM§32(9.3)Charlson comorbidity index02(0.6)128(8.1)263(18.3)395(27.6)460(17.4)557(16.6)625(7.3)79(2.6)85(1.5)BMI∥ (㎏/㎡)22.36 ± 3.56BMD¶ T-score(baseline)Spine− 2.58 ± 1.06Total hip− 1.64 ± 0.87Femoral neck− 2.63 ± 0.72Past fracture historyYes173(49.7)No171(50.3)*: denosumab, †: calcium, ‡: bisphosphonate, §: selective estrogen receptor modulator, ∥: body mass index, ¶: bone mineral density. Basic demographics of all subjects. *: denosumab, †: calcium, ‡: bisphosphonate, §: selective estrogen receptor modulator, ∥: body mass index, ¶: bone mineral density. Table 2 shows the demographic data for the group treated with denosumab, calcium, and vitamin D, as well as the group treated with denosumab alone. Statistically significant differences between the two groups were observed in prior osteoporosis treatment history (P = 0.004) and baseline spine BMD (P = 0.027). Table 2Baseline demographic characteristics of two groups.VariableN = 344P (< 0.05)Dmab* (N = 92)Dmab + Ca†, Vit D (N = 252)SexMale3(3.3)13(5.2)0.459Female89(96.7)239(94.8)Age(years)71.8 ± 9.170.0 ± 9.60.132 < 6520(21.7)71(28.2)0.46865–7432(34.8)84(33.3) ≥ 7540(43.5)97(38.5)Prior treatmentNo69(75.0)140(55.6)0.004*BP‡16(17.4)87(34.5)SERM§7(7.6)25(9.9)Charlson comorbidity index00(0.0)2(0.8)0.548112(13.0)16(6.3)218(19.6)45(17.9)320(21.7)75(29.8)417(18.5)43(17.1)514(15.2)43(17.1)68(8.7)17(6.7)72(2.2)7(2.8)81(1.1)4(1.6)BMI∥ (㎏/㎡)21.8 ± 3.122.6 ± 3.70.081BMD¶ T-score(baseline)Spine− 2.8 ± 0.9− 2.5 ± 1.10.027Total hip− 1.7 ± 0.9− 1.6 ± 0.80.424Femoral neck− 2.7 ± 0.8− 2.6 ± 0.70.504Past fracture historyYes52(43.5)121(52.0)0.163No40(56.5)131(48.0)*: denosumab, †: calcium, ‡: bisphosphonate, §: selective estrogen receptor modulator, ∥: body mass index, ¶: bone mineral density. Baseline demographic characteristics of two groups. *: denosumab, †: calcium, ‡: bisphosphonate, §: selective estrogen receptor modulator, ∥: body mass index, ¶: bone mineral density. The mean ± SD percent changes in BMD after one year of denosumab treatment among all 344 patients were 4.38 ± 5.41 at the lumbar spine, 2.07 ± 3.71 at the total hip, and 2.14 ± 4.99 at the femoral neck. The percent changes in BMD after two years of treatment were 6.89 ± 6.88 at the lumbar spine, 2.36 ± 5.09 at the total hip, and 3.52 ± 6.55 at the femoral neck (Table 3, Fig. 1). Table 3Bone mineral density changes of all 344 patients after 2 years denosumab treatment.Variable1 yr % changes (mean ± SD)2 yr % changes (mean ± SD)Spine4.38 ± 5.416.89 ± 6.88Total hip2.07 ± 3.712.36 ± 5.09Femoral neck2.14 ± 4.993.52 ± 6.55 Bone mineral density changes of all 344 patients after 2 years denosumab treatment. The mean percentage change in bone mineral density at the lumbar spine, total hip, and femoral neck from baseline in all 344 patients. In the one-way ANOVA analysis, the one-year mean ± SD percent changes from baseline in BMD at the lumbar spine, total hip, and femoral neck after treatment with denosumab alone were 3.86 ± 5.57, 2.45 ± 3.71, and 2.64 ± 4.94, respectively. The one-year mean ± SD percent changes from baseline in BMD at the lumbar spine, total hip, and femoral neck after treatment with denosumab, calcium, and vitamin D were 4.58 ± 5.35, 1.93 ± 3.70, and 1.96 ± 5.01, respectively. There was no statistically significant difference in BMD changes between the two groups after one year of treatment (Table 4, Fig. 2). Table 4Bone mineral density changes of two groups after 2 years denosumab treatment.VariableN = 344P (< 0.05)Dmab* (N = 92)Dmab + Ca†, Vit D (N = 252)Spine1 yr%3.86 ± 5.574.58 ± 5.350.2772 yr%6.89 ± 5.796.90 ± 7.240.989Total hip1 yr%2.45 ± 3.711.93 ± 3.700.2572 yr%2.40 ± 4.742.34 ± 5.230.924Femoral neck1 yr%2.64 ± 4.941.96 ± 5.010.2612 yr%3.91 ± 6.373.38 ± 6.620.506*: denosumab, †: calcium. Bone mineral density changes of two groups after 2 years denosumab treatment. *: denosumab, †: calcium. The mean average percentage change in bone mineral density from baseline at (A) the lumbar spine, (B) the total hip, and (C) the femoral neck, comparing the denosumab-only group with the denosumab plus calcium and vitamin D group at 1 and 2 years. Error bars represent 95% confidence intervals. Regardless of the type of osteoporosis medication used before denosumab treatment, there was no significant difference in the changes in BMD measured in each region at 1 and 2 years after denosumab treatment (Table 5). Table 5Bone mineral density changes after 2 years denosumab treatment based on history of prior osteoporosis treatment.VariableN = 344P (< 0.05)No treatment (N = 209)Prior BP* (N = 103)Prior SERM† (N = 32)Spine1 yr%4.66 ± 5.463.88 ± 5.624.24 ± 4.280.4842 yr%7.25 ± 7.096.34 ± 6.636.38 ± 6.240.501Total hip1 yr%2.01 ± 3.701.87 ± 3.723.08 ± 3.700.2532 yr%2.21 ± 5.202.58 ± 4.992.63 ± 4.840.796Femoral neck1 yr%2.42 ± 5.281.61 ± 4.462.07 ± 4.630.4082 yr%3.50 ± 6.233.03 ± 7.505.23 ± 4.950.251*: bisphosphonate, †: selective estrogen receptor modulator. Bone mineral density changes after 2 years denosumab treatment based on history of prior osteoporosis treatment. *: bisphosphonate, †: selective estrogen receptor modulator. Similarly, the presence or absence of a low-energy fragility fracture before denosumab administration did not significantly affect the change in BMD at 1 and 2 years after denosumab treatment (Table 6). Table 6Bone mineral density changes after 2 years denosumab treatment based on history of past osteoporotic fractures.VariableN = 344P (< 0.05)Past fracture history (N = 173)No history of fracture (N = 171)Spine1 yr%4.24 ± 6.294.53 ± 4.340.6252 yr%7.27 ± 7.776.51 ± 5.830.312Total hip1 yr%1.85 ± 3.842.29 ± 3.570.2752 yr%1.98 ± 5.202.74 ± 4.960.165Femoral neck1 yr%1.96 ± 5.812.33 ± 4.000.4992 yr%2.92 ± 7.634.12 ± 5.170.088 Bone mineral density changes after 2 years denosumab treatment based on history of past osteoporotic fractures. Subgroup analysis restricted to treatment-naïve patients (n = 209) showed no significant differences in lumbar spine, total hip, or femoral neck BMD gains between those who received calcium/vitamin D supplements and those who did not (all P > 0.05) (Table 7). Table 7Bone mineral density changes in treatment-naïve patients after 1 and 2 years of denosumab treatment, according to calcium and vitamin D supplementation.Treatment naïve patients (N = 209)P (< 0.05)Dmab* (N = 69)Dmab + Ca†, Vit D (N = 140)Spine1 yr%3.84 ± 5.615.06 ± 5.360.1292 yr%6.91 ± 5.957.41 ± 7.600.633Total hip1 yr%2.24 ± 3.531.90 ± 3.780.5332 yr%1.87 ± 4.352.38 ± 5.580.506Femoral neck1 yr%2.42 ± 4.992.41 ± 5.280.9902 yr%3.29 ± 6.713.60 ± 6.010.736 Bone mineral density changes in treatment-naïve patients after 1 and 2 years of denosumab treatment, according to calcium and vitamin D supplementation. Among the patients included in this study, none reported experiencing symptomatic side effects, such as infection at the injection site, myalgia, or symptomatic hypocalcemia, after receiving denosumab. Discussion Bisphosphonates (BPs) were the first class of drugs used for the treatment of osteoporosis, showing significant benefits in improving BMD and reducing fractures7–9,18. However, long-term use of BPs has been associated with serious adverse effects, including osteonecrosis of the jaw and atypical femoral fractures. These side effects have led to the recommendation of “drug holidays” to mitigate these risks19–23. Advances in bone biology have led to the development of denosumab, a fully human monoclonal antibody targeting RANKL4. Several studies have demonstrated that denosumab results in significant improvements in BMD. Specifically, after one year of treatment, BMD increases of 3.2–5.3% at the lumbar spine, 1.9–3.5% at the total hip, and 1.2–2.4% at the femoral neck have been observed24–27. Our study corroborates these findings, demonstrating that denosumab significantly improves BMD regardless of whether calcium and vitamin D supplements are administered. Calcium and vitamin D are crucial for bone health and calcium homeostasis, and their role in osteoporosis is well-documented. Despite their importance, the effectiveness of these supplements in preventing fractures and their potential cardiovascular risks remain contentious28,29. Bone tissue serves as a critical reservoir for calcium, and antiresorptive drugs such as BPs and denosumab inhibit osteoclastic bone resorption, thereby reducing the efflux of calcium from bone. This inhibition may lead to a transient period of mild hypocalcemia30,31. Consequently, calcium and vitamin D supplements are often prescribed alongside antiresorptive therapies. The majority of long-term clinical trials for osteoporosis treatments, including those pivotal for FDA approval, required that at least some patients take calcium supplements32. As a result, clinicians may have concerns about the therapeutic efficacy of antiresorptive drugs like BPs and denosumab in patients who do not take calcium and vitamin D supplements. Our study’s primary objective was to determine whether the effect of denosumab on BMD is altered in the absence of these supplements. Our findings show that there was no significant difference in BMD changes between patients who received calcium and vitamin D supplements and those who did not. This suggests that denosumab’s effect on BMD may not be critically dependent on calcium and vitamin D intake over a two-year period. Moreover, when comparing the treatment-naïve patients with those who had received prior treatment with BPs or selective estrogen receptor modulators (SERMs), slightly better BMD improvements were observed in the treatment-naïve group across all measurement sites. However, these differences did not reach statistical significance, which is consistent with previous studies reporting similar trends in BMD improvements between treatment-naïve and pretreated patients33. The importance of calcium and vitamin D supplementation may also depend on baseline nutritional status, including dietary calcium intake and pre-treatment vitamin D levels. Although these variables were not directly measured in our study, previous research in similar postmenopausal populations provides useful context. In a randomized controlled trial by Bonnick et al., postmenopausal women with a mean dietary calcium intake of approximately 1200 mg/day and vitamin D supplementation of 400 IU/day achieved substantial BMD gains with alendronate, whereas additional calcium supplementation conferred no further benefit11. In that population, higher baseline dietary calcium intake appeared sufficient to maintain bone metabolism without requiring extra supplementation. Future studies should therefore evaluate how baseline calcium and vitamin D levels influence denosumab efficacy in different nutritional contexts. Regarding the risk of hypocalcemia, its frequency as a complication associated with denosumab therapy varies widely across studies, ranging from 0.3 to 25.9%33–35. Risk factors for hypocalcemia following denosumab administration include impaired renal function and secondary hyperparathyroidism. Calcium and vitamin D supplementation is strongly recommended for these patients to mitigate the risk36. In the present study, we reviewed the electronic medical records of 344 patients, irrespective of whether they took calcium and vitamin D supplements, and found that none of the patients experienced symptomatic hypocalcemia during the study period. There are several limitations to this study that should be considered. First, due to the retrospective design of the study, there is a possibility that patients who discontinued denosumab due to side effects were not included in the analysis, potentially introducing selection bias. Second, we were unable to determine the incidence of asymptomatic hypocalcemia, as many patients did not undergo follow-up blood tests. Although no symptomatic hypocalcemia was observed, the risk remains for patients who do not receive calcium and vitamin D supplementation, and those who cannot tolerate these supplements should be informed of the potential risks and closely monitored. Lastly, this study did not assess the amount of calcium and vitamin D consumed through dietary sources, even among patients who did not use supplements. Dietary intake of calcium and vitamin D, sunlight exposure, and overall nutritional status may have influenced calcium homeostasis and bone metabolism, thereby potentially affecting the results. The absence of such dietary, biomechanical and nutritional data represents another limitation of this study. Future investigations should include assessments of dietary intake and related nutritional factors to better elucidate their roles in maintaining bone health, particularly in patients who are not taking supplements. Conclusion Our study suggests that denosumab may be effective in improving BMD, regardless of calcium and vitamin D supplementation. Although supplementation is commonly recommended, it may not be essential for achieving meaningful improvements in bone density with denosumab over a two-year period. Nevertheless, careful monitoring for hypocalcemia remains important, particularly in patients who do not take supplements. Further studies with biochemical and fracture outcome data are warranted to clarify these associations. Author contributions YHC contributed to data collection, data processing, and writing of the manuscript. SEB performed formal analysis, proofreading, and review. HHL contributed to data processing, formal analysis, and was responsible for review and editing. All authors have read and approved the final manuscript. Data availability The datasets for this study can be obtained from the corresponding author upon any reasonable request. Declarations Competing interests The authors declare no competing interests Ethical approval This study was approved by the Institutional Review Board (IRB) of Daegu Fatima Hospital (IRB No. DFH 2024-11-002), and all methods were performed in accordance with relevant guidelines and regulations, including the Declaration of Helsinki. The requirement for informed consent was waived by the IRB due to the retrospective nature of the study. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Seong-Eun Byun, Email: sonofos@daum.net. Hwan-Hee Lee, Email: hwanhee337@naver.com. References Associated Data Data Availability Statement The datasets for this study can be obtained from the corresponding author upon any reasonable request.